CClinicalTrials.gg
Not yet recruitingNCT06201715Updated Apr 1, 2024

Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis

An interventional study of Tofacitinib 5 MG in Prurigo Nodularis and Itch, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-01.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal is to evaluate the efficacy and safety of tofacitinib in treating refractory prurigo nodularis.The main questions it aims to answer are

  1. whether tofacitinib is effective in treating prurigo nodularis in the longpterm.
  2. whether tofacitinib is safe in prurigo nodularis patients in the longpterm.
02

Conditions studied

  • Prurigo Nodularis
  • Itch
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. age ≥18 years old;
  2. patients diagnosed with PN with a duration of more than 6 months;
  3. presence of at least 10 pruritic nodules;
  4. a Worst Itch-Numeric Rating Scale (WI-NRS) score ≥7 one week before study;
  5. a history of more than 2 weeks of ineffective topical glucocorticoid treatment or antihistamine therapy;
  6. signed informed consent and cooperated with the follow up and complied the study protocol.

Exclusion criteria

Exclusion criteria:

  1. current used of biologic, systemic glucocorticoid or immunosuppressive agents; past used of jak inhibitors;
  2. were pregnant or lactating;
  3. abnormal findings for patients' complete blood count, liver functions, and kidney function tests;
  4. presence of any infection or inflammatory; presence of active tumors or an increased risk of tumor complications;
  5. systemic comorbidities that could interfere with or complicate study assessments.
  6. those experiencing atopic dermatitis within 6 months were excluded from this study.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    tofacitinib

    Drug: Tofacitinib 5 MG

Interventions

  • DrugTofacitinib 5 MG

    5mg tofacitinib tablet twice daily

05

What researchers measure

Primary outcomes

  1. Investigator's global assessment

    a 11-point scale ranging from -5 (obvious aggravation) to 5(marked improvement) points.

    Time frame: up to 12 weeks

  2. Prurigo Activity Score

    The PAS is a 7-item questionnaire evaluating the type, distribution and size of pruriginous lesions, the representative body area and exact number of lesions, the activity in the terms of percentage of pruriginous lesions with excoriations/crusts on top and the percentage of healed pruriginous lesions, which is proved to be a useful tool to objectively measure PN patients over time.

    Time frame: up to 12 weeks

  3. Visual analogue scale (VAS) at week 12

    The VAS is a visual scale for itch on a horizontal 10-cm line, on which the left end is marked as "no itch" and the right end is marked "worst imaginable itch". We defined the average pruritus of the past 24 hours as VAS24h, average, and the worst and average pruritus of the past 4 weeks as VAS4w, worst and VAS4w, average.

    Time frame: up to 12 weeks

  4. Numeric rating scale at week 12

    The NRS is a similar tool for the measurement of itch ranging from 0 (no itch) to 10 (unbearable itch). Similarly, we defined the average and worst pruritus of the past 24 hours using NRS as NRS24h, average and NRS24h, worst.

    Time frame: up to 12 weeks

  5. Verbal rating scale (VRS) at week 12

    The VRS is a 5-point questionnaire that indicated different itching intensities as follows: 0=none; 1=mild; 2=moderate; 3=severe; 4= very severe. The VRS24h, average, VRS24h, worst and VRSevening represented 24-hour average, worst as well as average evening pruritus by VRS.

    Time frame: up to 12 weeks

  6. Dermatology Life Quality Index (DLQI) at week 12

    The DLQI is a questionnaire with scores ranging from 0 to 30. The total scores of 30 points represent the worst possible quality of life due to pruritus and a change of the score of ≥4 points is considered to be clinically important.

    Time frame: up to 12 weeks

  7. Itchy specific quality of life (Itchy QoL) at week 12

    The Itchy QoL includes 22 pruritus-specific items as follows: 6 symptoms, 7 functional limitation, and 9 emotions.

    Time frame: up to 12 weeks

Secondary outcomes

  1. the proportion of patients with reduction in WI-NRS by ≥4 points from baseline at week 12 and week 16.

    WI-NRS represents Worst Itch-Numeric Rating Scale score

    Time frame: up to 16 weeks

06

Study locations

1 site
  • Second Affiliated Hospital, School of Medicine, Zhejiang University, China
    Hangzhou, Zhejiang 310009, China
07

References and documents

Individual participant data

Plan to share: No — The data that support the findings of this study are not publicly available due to the privacy of research participants but are available from the sponsor upon reasonable request.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06201715
Lead sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Responsible party
Sponsor
First posted
Jan 11, 2024
Start date
May 1, 2024 (estimated)
Primary completion
Jun 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Apr 1, 2024

Study contacts

Ru Dai
Contact
dairu@zju.edu.cn
+8615982215914

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion